Literature DB >> 19923482

Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile.

Ann M Larson1, Angela M Fung, Ferric C Fang.   

Abstract

Clostridium difficile is the most common infectious cause of diarrhea in hospitalized patients. The optimal approach for the detection of toxigenic C. difficile remains controversial because no single test is sensitive, specific, and affordable. We have developed a real-time PCR method (direct stool PCR [DPCR]) to detect the tcdB gene encoding toxin B directly from stool specimens and have combined it with enzyme immunoassays (EIAs) in a three-step protocol. DPCR was performed on 699 specimens that were positive for C. difficile glutamate dehydrogenase (GDH) by Wampole C Diff Quik Chek EIA (GDH-Q) and negative for toxins A and B by Wampole Tox A/B Quik Chek EIA (AB-Q), performed sequentially. The performance of this three-step algorithm was compared with a modified "gold standard" that combined tissue culture cytotoxicity (CYT) and DPCR. A separate investigation was performed to evaluate the sensitivity of the GDH-Q as a screening test, and toxigenic C. difficile was found in 1.9% of 211 GDH-Q-negative specimens. The overall sensitivity, specificity, and positive and negative predictive values, respectively, were as follows for an algorithm combining GDH-Q, AB-Q, and DPCR: 83.8%, 99.7%, 97.1%, and 97.9%. Those for CYT alone were 58.8%, 100%, 100%, and 94.9%, respectively. In comparison, the sensitivity and specificity of DPCR were estimated to be 97.5% and 99.7%, respectively, using the same modified gold standard. Neither CYT nor toxin EIA was sufficiently sensitive to exclude toxigenic C. difficile, and combining EIAs with CYT in a three-step algorithm failed to substantially improve sensitivity. DPCR is a sensitive and specific method for the detection of toxigenic C. difficile that can provide same-day results at a cost-per-positive test comparable to those of other methods. A three-step algorithm in which DPCR is used to analyze GDH EIA-positive, toxin EIA-negative specimens provides a convenient and specific alternative with rapid results for 87.7% of specimens, although this approach is less sensitive than performing DPCR on all specimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19923482      PMCID: PMC2812255          DOI: 10.1128/JCM.00734-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  56 in total

1.  Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases.

Authors:  F Barbut; V Lalande; G Daprey; P Cohen; N Marle; B Burghoffer; J C Petit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-06       Impact factor: 3.267

Review 2.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

3.  High prevalence of toxin A-negative toxin B-positive Clostridium difficile in hospitalized patients with gastrointestinal disease.

Authors:  Zmira Samra; Smadar Talmor; Judi Bahar
Journal:  Diagn Microbiol Infect Dis       Date:  2002-07       Impact factor: 2.803

4.  "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD.

Authors:  E Bouza; T Peláez; R Alonso; P Catalán; P Muñoz; M R Créixems
Journal:  J Hosp Infect       Date:  2001-07       Impact factor: 3.926

5.  Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.

Authors:  M J Alfa; A Kabani; D Lyerly; S Moncrief; L M Neville; A Al-Barrak; G K Harding; B Dyck; K Olekson; J M Embil
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

6.  Development and evaluation of a PCR method for detection of the Clostridium difficile toxin B gene in stool specimens.

Authors:  C Guilbault; A-C Labbé; L Poirier; L Busque; C Béliveau; M Laverdière
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

7.  Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Authors:  Lorraine Kyne; Mary Beth Hamel; Rajashekhar Polavaram; Ciarán P Kelly
Journal:  Clin Infect Dis       Date:  2001-12-17       Impact factor: 9.079

8.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays.

Authors:  M J Alfa; B Swan; B VanDekerkhove; P Pang; G K M Harding
Journal:  Diagn Microbiol Infect Dis       Date:  2002-08       Impact factor: 2.803

10.  Toxin B is essential for virulence of Clostridium difficile.

Authors:  Dena Lyras; Jennifer R O'Connor; Pauline M Howarth; Susan P Sambol; Glen P Carter; Tongted Phumoonna; Rachael Poon; Vicki Adams; Gayatri Vedantam; Stuart Johnson; Dale N Gerding; Julian I Rood
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962

View more
  35 in total

1.  Glutamate dehydrogenase for laboratory diagnosis of Clostridium difficile infection.

Authors:  Simon D Goldenberg; Penny R Cliff; Gary L French
Journal:  J Clin Microbiol       Date:  2010-08       Impact factor: 5.948

2.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 4.  Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty?

Authors:  Fred C Tenover; Ellen Jo Baron; Lance R Peterson; David H Persing
Journal:  J Mol Diagn       Date:  2011-08-18       Impact factor: 5.568

5.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

Review 6.  Laboratory diagnosis of bacterial gastroenteritis.

Authors:  Romney M Humphries; Andrea J Linscott
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

7.  Clostridium difficile infection: risk factors, diagnosis and management.

Authors:  Christina M Surawicz
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 8.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

9.  Comparison of five assays for detection of Clostridium difficile toxin.

Authors:  Kimberle C Chapin; Roberta A Dickenson; Fongman Wu; Sarah B Andrea
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

10.  Similar outcomes of IBD inpatients with Clostridium difficile infection detected by ELISA or PCR assay.

Authors:  Yinghong Wang; Ashish Atreja; Xianrui Wu; Bret A Lashner; Aaron Brzezinski; Bo Shen
Journal:  Dig Dis Sci       Date:  2013-03-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.